Robert Fungo,Francis Zotor,Andrew Prentice et al.
Robert Fungo et al.
Richard Horton
Richard Horton
Jean M Seely,Paula B Gordon
Jean M Seely
The Lancet
The Lancet
Martijn G J de Neeling,Bart J Keulen,Mariëlle J Stam et al.
Martijn G J de Neeling et al.
With the introduction of adaptive deep brain stimulation (aDBS) for Parkinson's disease, new questions emerge regarding who, why, and how to treat. This paper outlines the pathophysiological rationale for aDBS, which provides real-time modu...
Charlotte L LeJeune,Kristel Van Calsteren,Thaïs Baert et al.
Charlotte L LeJeune et al.
Alla Hill,Peter Lurie,Lawrence O Gostin
Alla Hill
Guido Gembillo,Luca Soraci,Domenico Santoro
Guido Gembillo
Ingrid de Zwarte,Alex de Waal,L H Lumey
Ingrid de Zwarte
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study [0.03%]
关于边缘区淋巴瘤复发或难治性患者的lisocabtagene maraleucel治疗：全球多队列单臂二期试验的主要分析结果（TRANSCEND FL）
M Lia Palomba,Stephen J Schuster,Reem Karmali et al.
M Lia Palomba et al.
Background: Effective treatments with deep and durable responses for relapsed or refractory marginal zone lymphoma (MZL) are lacking. The objective of the primary analysis from the MZL cohort of TRANSCEND FL was to evalua...